19 September 2016 - The U.S. FDA has approved Bayer AG’s new low dose levonorgestrel-releasing intrauterine system which will be marketed in the US under the brand name Kyleena.

Kyleena releases the lowest daily dose of the hormone levonorgestrel in an intrauterine system for up to five years of effective protection against pregnancy, using the smallest T-shaped body in an IUS available today. Long-acting contraception is one of the most effective methods of birth control as it does not require user interventions such as daily dosing or monthly re-fills. An levonorgestrel-releassing intrauterine system can be removed at any time and offers rapid return to a woman’s natural level of fertility after removal.

Read Bayer press release